Elanco Animal Health's (ELAN) Hold (C-) Rating Reaffirmed at Weiss Ratings

Key Points

• Elanco Animal Health's stock has a "hold (C-)" rating reaffirmed by Weiss Ratings, signaling a cautious outlook from analysts.
• Multiple analysts have raised their price targets for Elanco, with estimates ranging from $18.00 to $25.00 and ratings varied from "strong-buy" to "buy."
• Elanco reported strong quarterly earnings, with an EPS of $0.26 exceeding estimates, alongside a revenue increase of 4.8% year-over-year.

Elanco Animal Health (NYSE:ELAN - Get Free Report)'s stock had its "hold (c-)" rating restated by research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

ELAN has been the subject of a number of other research reports. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a report on Thursday, July 17th. UBS Group increased their price target on Elanco Animal Health from $19.00 to $25.00 and gave the company a "buy" rating in a report on Monday, October 20th. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, JPMorgan Chase & Co. raised Elanco Animal Health from a "neutral" rating to an "overweight" rating and increased their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of "Moderate Buy" and an average price target of $20.00.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $22.10 on Friday. The business has a 50 day simple moving average of $19.31 and a two-hundred day simple moving average of $15.18. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $22.26. The stock has a market capitalization of $10.98 billion, a P/E ratio of 25.70, a PEG ratio of 3.99 and a beta of 1.65. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The business's revenue was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. MTM Investment Management LLC grew its position in Elanco Animal Health by 5.5% in the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company's stock worth $218,000 after acquiring an additional 800 shares during the period. HighTower Advisors LLC grew its position in Elanco Animal Health by 7.0% in the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company's stock worth $131,000 after acquiring an additional 810 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Elanco Animal Health by 8.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company's stock worth $169,000 after acquiring an additional 944 shares during the period. Farther Finance Advisors LLC grew its position in Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock worth $43,000 after acquiring an additional 951 shares during the period. Finally, M&T Bank Corp grew its position in Elanco Animal Health by 4.0% in the second quarter. M&T Bank Corp now owns 25,029 shares of the company's stock worth $358,000 after acquiring an additional 971 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.